PE20141817A1 - Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv - Google Patents

Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv

Info

Publication number
PE20141817A1
PE20141817A1 PE2014001095A PE2014001095A PE20141817A1 PE 20141817 A1 PE20141817 A1 PE 20141817A1 PE 2014001095 A PE2014001095 A PE 2014001095A PE 2014001095 A PE2014001095 A PE 2014001095A PE 20141817 A1 PE20141817 A1 PE 20141817A1
Authority
PE
Peru
Prior art keywords
composition
powerful
pharmaceutical formulations
refers
stabilized pharmaceutical
Prior art date
Application number
PE2014001095A
Other languages
English (en)
Spanish (es)
Inventor
Mathias Braun
Carl Alan Busacca
Feng-Jing Chen
Edwin Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20141817A1 publication Critical patent/PE20141817A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014001095A 2012-01-12 2013-01-10 Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv PE20141817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
PE20141817A1 true PE20141817A1 (es) 2014-12-17

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001095A PE20141817A1 (es) 2012-01-12 2013-01-10 Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv

Country Status (27)

Country Link
US (2) US20140037719A1 (enEXAMPLES)
EP (1) EP2802313A1 (enEXAMPLES)
JP (1) JP2015503616A (enEXAMPLES)
KR (1) KR20140109433A (enEXAMPLES)
CN (1) CN104244926A (enEXAMPLES)
AP (1) AP2014007760A0 (enEXAMPLES)
AR (1) AR089710A1 (enEXAMPLES)
AU (1) AU2013208024A1 (enEXAMPLES)
BR (1) BR112014017058A8 (enEXAMPLES)
CA (1) CA2861041A1 (enEXAMPLES)
CL (1) CL2014001783A1 (enEXAMPLES)
CO (1) CO7000774A2 (enEXAMPLES)
EA (1) EA201400808A1 (enEXAMPLES)
EC (1) ECSP14013104A (enEXAMPLES)
HK (1) HK1204982A1 (enEXAMPLES)
IL (1) IL233550A0 (enEXAMPLES)
IN (1) IN2014DN05759A (enEXAMPLES)
MA (1) MA35865B1 (enEXAMPLES)
MX (1) MX2014008205A (enEXAMPLES)
NZ (1) NZ626353A (enEXAMPLES)
PE (1) PE20141817A1 (enEXAMPLES)
PH (1) PH12014501598A1 (enEXAMPLES)
SG (1) SG11201404042VA (enEXAMPLES)
TN (1) TN2014000295A1 (enEXAMPLES)
TW (1) TW201340969A (enEXAMPLES)
UY (1) UY34569A (enEXAMPLES)
WO (1) WO2013106506A1 (enEXAMPLES)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EP2970335B1 (en) 2013-03-15 2019-05-08 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
EA018603B1 (ru) 2008-09-16 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
SI2358355T1 (sl) * 2008-11-21 2014-02-28 Boehringer Ingelheim Gmbh Farmacevtski sestavek potentnega inhibitorja HCV za oralno dajanje
PL2451438T3 (pl) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
PH12014501598A1 (en) 2014-10-08
ECSP14013104A (es) 2015-11-30
AU2013208024A1 (en) 2014-07-10
IL233550A0 (en) 2014-08-31
EP2802313A1 (en) 2014-11-19
NZ626353A (en) 2016-02-26
KR20140109433A (ko) 2014-09-15
BR112014017058A2 (pt) 2017-06-13
US20150190458A1 (en) 2015-07-09
MA35865B1 (fr) 2014-12-01
US20140037719A1 (en) 2014-02-06
TW201340969A (zh) 2013-10-16
CO7000774A2 (es) 2014-07-21
CL2014001783A1 (es) 2014-12-12
MX2014008205A (es) 2014-08-08
CA2861041A1 (en) 2013-07-18
EA201400808A1 (ru) 2015-02-27
CN104244926A (zh) 2014-12-24
AP2014007760A0 (en) 2014-07-31
JP2015503616A (ja) 2015-02-02
HK1204982A1 (en) 2015-12-11
TN2014000295A1 (en) 2015-12-21
UY34569A (es) 2013-07-31
SG11201404042VA (en) 2014-08-28
IN2014DN05759A (enEXAMPLES) 2015-04-10
WO2013106506A1 (en) 2013-07-18
AR089710A1 (es) 2014-09-10
BR112014017058A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
HK1247843A1 (zh) 具有受控吸收曲线的用於口服给药活性剂的制剂
NZ600816A (en) Inhibitors of flaviviridae viruses
PE20141056A1 (es) Metodos para el tratamiento de vhc
BR112012023021A2 (pt) compostos de indazol e seus usos
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
PE20140255A1 (es) Tableta dispersable en forma oral
UY32127A (es) Granulado conteniendo nicotina con muy reducida o nula producción de polvo en procesos donde se utilice y procedimientos de preparación
TN2012000135A1 (en) Cyclic peptide inhibitors of hepatitis c virus replication
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
BR112013020042A2 (pt) inibidores de vírus da hepatite c
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
BR112013028679A2 (pt) inibidores do vírus da hepatite c
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
ECSP12011699A (es) Tableta
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
PE20141817A1 (es) Formulaciones farmaceuticas estabilizadas de un potente inhibidor de hcv
PE20080250A1 (es) Proceso para la precipitacion y el aislamiento de compuestos 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen dicho compuesto
CO6612211A2 (es) Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas
BR112013020195A2 (pt) composições farmacêuticas livres de citrato compreendendo anakinra
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
PH12013500027A1 (en) Therapeutic agents 976
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа

Legal Events

Date Code Title Description
FD Application declared void or lapsed